updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
iqvia formerli quintilesim result merger
quintil lead late-stag contract research organ
im health domin player life scienc data analyt
long-term strateg benefit merger remain somewhat
uncertain question compani
entrench leader cro space life scienc data
analyt result merger compani lead
real-world evid data sourc patient
record medic claim use creat clinic evid
regulatori approv
revenu come research
develop segment outsourc clinic research
technolog analyt segment legaci im health
real-world data solut contract sale
research develop segment focus late-stag
research requir thousand patient across globe
iqvia one global infrastructur win
contract size mean work clinic trial
competitor sharpen clinic regulatori
compani comprehens data set de-identifi patient
record script data enhanc abil attract retain
healthcar custom throughout life cycl drug product
iqvia compil data sourc includ
pharmaci medic claim electron health record
access million patient record unmatch data
set layer proprietari methodolog enabl client set
inform strategi effect commerci drug
result busi command price premium high
retent rate exist client access data help inform
patient identif clinic trial success trial design
true advantag lie real-world evid
cohort de-identifi patient data set use lieu
tradit clinic trial cohort regulatori approv
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
iqvia result merger quintil lead global contract
research organ im health lead healthcar data
analyt provid cro segment focus primarili provid
outsourc late-stag clinic trial pharmaceut devic
technolog servic client healthcar industri includ
pharmaceut compani provid payer policymak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
iqvia report respect top-lin growth total
revenu billion constant currenc
adjust foreign exchang headwind roughli
million quarter adjust basi revenu came
within expect cost revenu tick
ahead expect grow year year
nearli sequenti cost driven
acceler technolog deploy third quarter
mix shift away high-margin data busi
essenti flat compani revis full-year guidanc
lower top-lin guidanc due foreign exchang
effect
adjust currenc headwind top line higher
cost expect maintain fair valu
estim per share narrow moat rate
remain unchang well mid-single-digit
pullback share price morn oct
continu believ share look overvalu market
extrapol top line overperform unreason
expect margin improv
iqvia moat built intang asset associ
execut complex clinic trial well
switch cost engrain client relationship
evidenc compani moatworthi data busi
remain flat also remain wide use across
biopharma industri compani leverag network
client relationship legaci data busi sell
technolog solut saw win third
quarter includ busi two pharma
market think iqvia offer compel valu
proposit solut benefit power
brand howev think win deploy
requir continu invest result slow
iqvia pioneer industri effort util real-
world data clinic trial real-world evid
rwe trial remain small portion revenu call
manag indic iqvia project use
extern compar arm quadrupl last
month project includ recent win
pharma client europ hematology/oncolog
encourag anecdot indic rwe gain
traction rel competitor iqvia best posit
leverag unmatch patient databas analyt
rais fair valu estim per share
adjust midterm revenu outlook
compani follow investor day fair
valu estim driven mid- high-single-digit top-lin
growth oper margin improv continu
tuck-in acquisit impli enterpris valu
time adjust ebitda forward price-to-earnings ratio
time
continu win
expect cro industri grow midsingl digit
due low-single-digit growth biopharma research
develop spend well modest increas
outsourc penetr believ iqvia gain
share cro space research develop
segment grow slightli higher clip industri
rate billion revenu
believ technolog analyt segment
grow faster rate life scienc data analyt play
larger role clinic trial mission-crit
process biopharma industri model
five-year revenu compound-annual-growth-rate
billion revenu expect small contract
sale segment return low-single-digit growth
see opportun cut cost research
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
competit data analyt space
market either due slowdown global spend
biopharma industri hit macroeconom
headwind declin outsourc penetr
biopharma bring clinic trial process hous
competitor veeva gain share life
scienc data space case revenu
billion case cost expand due high salari need
retain talent oper margin
year forecast result
bear-cas fair valu estim per share
bull case assum iqvia address market
expand due faster-than-expect growth research
develop spend higher level outsourc
quick uptak real-world evid trial iqvia
abl effect differenti data analyt
offer competitor case firm earn
billion revenu case assum iqvia
improv gross oper margin util
capac effici abl adapt better
trial cancel result mid-cycle oper
margin bull-cas fair valu estim
iqvia leader clinic research healthcar data
nearli everi major biotechnolog pharmaceut
compani pay
proprietari data clinic develop expertis
posit firm well closest peer
intang asset high switch cost underpin
servic think
iqvia result merger im health
lead data analyt compani life scienc
develop segment model ebitda margin
improv basi point expect
iqvia push fixed-pric contract contract
visibl cost allow retain higher
margin think room margin expans
technolog analyt segment throughout
explicit forecast model basi point ebitda
margin improv addit autom
help reduc cost expect mix play role well
growth higher-margin real-world evid trial
use de-identifi patient data cohort evid
model long-term effect tax rate believ
firm continu grow acquir smaller cro
relat technolog compani model continu
tuck-in acquisit assum mid-cycle
capit expenditur sale
believ iqvia medium uncertainti rate due
vulner biopharma research develop
spend outsourc level well potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
quintil global cro largest market share
strateg advantag merger initi clear
im health provid data biotechnolog
pharmaceut compani rather lack
cro demand im health capabl littl
overlap two firm threw question whether
firm would abl achiev synergi whether
integr would smooth view data
analyt capabl im health posit advantag
iqvia util vast patient data inform clinic trial
plan execut recent interest real-world
evid trial data sourc patient
record medic claim use creat clinic
increas import data analyt cro
space believ iqvia signific cro market
share unparallel data capabl best posit
lead way real-world evid work compar
peer largest cro iqvia abil
influenc industri trend includ move data
analyt follow im health quintil merger
sever began build data capabl
acquisit partnership albeit lesser degre
real-world data trend earli day view
recent rhetor food drug administr
includ set guidelin decemb
posit indic potenti real-world evid
firm cro busi moatworthi right
infrastructur diversifi client base
late-stag exposur believ exposur late-stag
clinic trial crucial moat cro space
late-stag trial larger scope complex often
multi-national higher risk failur
differenti global leverag expertis
shorten clinic trial time frame ensur accuraci
precis iqvia maintain top spot cro market
central
share cro revenu come late-stag
work firm diversifi client base split
small/mids custom
larger biotech
pharmaceut compani broad portfolio
commerci believ diversifi client base
strengthen iqvia competit advantag small/mids
client like need full outsourc solut
partnership high switch cost choos one
trust funnel new
iqvia data analyt busi also deserv moat
due intang asset switch cost
proprietari data set sourc sourc
pharmaci claim registri patient record
scale data best-in-class analyt
technolog iqvia layer data creat high barrier
entri closest competitor iqvia technolog side
symphoni health offer smaller portfolio
data servic much smaller market share
veeva compet iqvia client relationship
manag increasingli data analyt
veeva captur signific share life scienc
cloud servic space believ iqvia reput
asset data space unparallel evidenc
retent rate top client
biotech pharmaceut client use iqvia servic
mission-crit function plan new product
launch forecast revenu market sell
client like continu choos trust iqvia data
believ iqvia stabl moat trend competit
dynam cro data space fundament
shift compani strategi consult
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
technolog aspect busi grow import
iqvia remain well posit space due
expans intang asset opinion believ
firm continu hold top share cro space due
exposur late-stag trial breadth
expertis complex diseas area diversifi client
base recent book backlog metric indic
cro industri continu grow
percentag outsourc grow slowli
data space iqvia advantag util
vast proprietari data capabl inform real-world
evid strategi sourc patient record
medic claim provid data regulatori approv
fda biopharma industri voic need
modern clinic trial process heavili
reli technolog believ difficulti obtain
extens databas develop best-in-class
technolog creat high barrier entri believ
grow market support smaller competitor
symphoni veeva without endang iqvia narrow
moat would consid upgrad posit moat trend
rate signific polici come fda
would make real-world evid preval
entrench iqvia data technolog advantag
would consid downgrad neg moat trend rate
shift data privaci regul interoper
initi lower barrier entri make easier
competitor encroach compani lead patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oiqvia lead posit outsourc clinic trial
allow creat sticki client relationship
hone clinic regulatori expertis
traction among client fail gain traction
oth merger im health provid access
unparallel databas patient data
strengthen clinic trial offer
oth on-going shift outsourc provid
cro industri steadi growth regardless
trend global research develop spend
oiqvia contract sale segment larg no-moat
busi lack competit advantag
ochang data privaci regul could
make easier competitor gain access de-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
iqvia decent financi health strong cash flow
gener clinic research technolog
busi assuag concern larg debt
load merger end compani
billion total gross debt debt time
adjust ebitda firm million cash
balanc sheet expect gener
billion oper cash flow expect healthi
cash gener clinic research
technolog segment concern
compani meet debt oblig matur
iqvia long-term debt
floating-r debt expect compani alloc
capit share buyback smaller acquisit
throughout explicit forecast period
cro industri highli depend spend
outsourc prefer custom base biotech
pharmaceut compani believ
decreas spend outsourc like
near term left expos risk
biopharma fund constrain chang
drug approv regulatori landscap biopharma
industri face macroeconom headwind iqvia
largest player cro space well-diversifi
revenu base singl client make
sale result think compani well
diversifi client concentr
risk
individu trial cancel sizabl impact
cro busi result compani also suscept
shift clinic trial data privaci regul
leader real-world evid iqvia success
highli depend regulatori cooper real-world
evid offer worth premium
complet embrac fda regulatori
entiti compani oper depend heavili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
use de-identifi patient data technolog
analyt segment well research develop
segment chang privaci guidelin could affect
suppli use data make easier competitor
amass patient data
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chairman board/president/
repres date owner name posit common share held report holder issuer
leadership team appropri experi span
consult clinic research healthcar data
analyt quintil im health merger
strateg bet futur data analyt
clinic research space note transact
significantli decreas level adjust return
invest capit roic believ one
import measur sharehold valu prior
merger quintil busi enjoy sky-high return
invest capit care execut manag
believ roic increas steadili compani
integr continu watch iqvia
leverag im data analyt asset
merger late bousbib former im
health ceo board chairman took posit
combin compani bousbib led im health sinc
hold sever leadership role unit
technolog think compani capit alloc
rel shareholder-friendli leadership
merger former quintil ceo thoma pike serv
vice chairman presid solut
retir compani coupl month later
pike earli departur rais eyebrow think cro
busi remain steadi hand leadership
 richard staub join quintil
acquisit specialti cro novella clinic
technolog segment led kevin knightli work
im year jon resnick presid
real-world analyt solut work im
share
fund
share
fund
prefer see chairman ceo role
separ remaind board made
independ director director
design privat equiti sharehold tpg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
design two director own outstand
share februari one director design
canada pension invest board
bain capit leonard green partner
tpg cppib leonard green took im privat
presenc privat equiti uncommon
cro industri mani top global player previous
restructur current firm period privat
equiti ownership believ owner interest
align minor sharehold note could
deviat long term denni gill found
quintil own share retir
board director april
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
narrow-moat iqvia see continu growth
iqvia post solid second-quart result revenu
billion repres growth constant
currenc adjust ebitda million repres
margin improv basi point last year
manag rais revenu guidanc full year
slightli narrow adjust ebitda guidanc rais
guidanc adjust earn per share may
make adjust model expect
materi chang fair valu estim per share
narrow moat rate
compani two key segment technolog analyt
research develop perform well
tech segment contribut billion last
year research segment contribut billion
last year intang asset custom
switch cost associ busi
foundat narrow econom moat rate third
much smaller segment contract sale medic
solut return growth constant currenc basi
indic stabil struggl busi
tech segment oce iqvia custom relationship
manag cloud solut garner win
sinc launch roughli month ago face
signific challeng competitor veeva hold
domin posit space research segment
compani continu benefit strong oper
environ mark continu drug innov
robust fund biotechnolog compani overal year-
to-dat expens track slightli higher
expect iqvia continu invest busi
push data-driven clinic trial solut name smart
trial howev manag indic expect
cost front-weight
maintain forecast point
iqvia announc compani name prefer
provid larg pharmaceut client
project relat real-world evid plan iqvia
strong posit real-world evid use data
inform clinic trial even replac trial arm key
sourc growth prospect next sever year
thank vast wealth data legaci im health
busi iqvia posit domin real-world
compani net leverag ratio time adjust
ebitda slight improv first quarter
time announc recent investor day iqvia aim
get time end
iqvia like continu util debt intern
invest share repurchas past
iqvia life scienc cloud busi continu soar
rais fve follow investor day jun
rais fair valu estim iqvia per
share follow investor day june
manag laid strategi growth
well plan addit cost save
de-lever compani continu fire cylind
strong growth key segment technolog
analyt research develop continu
believ share look rich believ narrow-
moat compani competit well posit life
scienc technolog contract research space
compani unveil midterm guidanc guid
three-year revenu compound-annual-growth-rate adjust
ebitda growth higher
previous model manag also
review goal laid outset quintil
im health merger late includ mid-single-
digit revenu growth adjust ebitda growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
reduc net leverag time adjust ebitda
million merger cost synergi goal
met testament manag
execut robust oper environ within
biopharma space driven innov new drug
well solid fund biotech
new valuat larg driven faster revenu growth
technolog analyt research
develop one top contract research
organ world expect research
develop segment continu grow slightli faster
industri iqvia take share smaller
segment model revenu compound-annual-growth-rate
within manag guidanc
believ iqvia solut solut data
analyt real-world evid under-penetrated
model revenu compound-annual-growth-rate near
midpoint manag midterm guidanc
wide-moat veeva difficult displac life
scienc cloud solut iqvia hold advantag
uniqu dataset legaci im best-in-class
iqvia
establish relationship major biopharma
player whether data busi cro
busi last sever quarter iqvia
reinvest significantli oce offer
recent announc intent launch safety-rel
solut commerci complianc pharmacovigil
encroach veeva territori expect real-
world evid involv use real-world data
patient inform clinic trial design execut
even serv virtual arm trial continu slowli
gain traction industri iqvia best posit
benefit trend clinic trial given breadth
data analyt
compani also announc intent uncov
addit million cost save top
already-met goal million
materi affect fair valu estim alreadi
model margin improv next sever
year compar pure-play peer veeva
icon think iqvia room oper leaner level
addit compani guidanc signal intent
de-lever net leverag target time
adjust ebitda end compani end
gross debt billion net leverag
ratio time iqvia net leverag end
roughli par peer syneo health
took debt merger target time
less net leverag ratio peer
icon health much debt use stock
repurchas averag repurchas price per share
sinc merger per share roughli
billion capit deploy sinc merger billion
use buy back share rest reinvest
busi use tuck-in acquisit
key target manag adjust ep growth
main pillar execut compens program along
adjust ebitda growth slightli lesser extent
revenu growth total sharehold return rel
peer think manag appropri
invest core busi believ stewardship could
improv rapid debt reduct
compani intend pace regardless reassur
compani confirm plan debt reduct
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
